CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 61,300 shares, a decline of 6.6% from the December 15th total of 65,600 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average daily trading volume, of 59,400 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of CalciMedica in a research report on Thursday, November 14th.

CalciMedica Trading Down 2.5 %

Shares of CALC stock traded down $0.08 during midday trading on Friday, reaching $3.09. 21,907 shares of the stock were exchanged, compared to its average volume of 25,828. CalciMedica has a 1 year low of $2.05 and a 1 year high of $8.38. The firm has a market cap of $41.65 million, a PE ratio of -2.86 and a beta of 1.22. The company’s 50 day moving average is $3.13 and its two-hundred day moving average is $3.86.

Insider Buying and Selling

In other CalciMedica news, insider Eric W. Roberts bought 53,333 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average cost of $3.75 per share, with a total value of $199,998.75. Following the completion of the purchase, the insider now directly owns 164,706 shares of the company’s stock, valued at $617,647.50. This trade represents a 47.89 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO A. Rachel Leheny purchased 20,000 shares of the stock in a transaction on Friday, November 1st. The shares were acquired at an average cost of $3.75 per share, with a total value of $75,000.00. Following the transaction, the chief executive officer now directly owns 130,926 shares in the company, valued at $490,972.50. The trade was a 18.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 252,744 shares of company stock valued at $942,510 over the last three months. 41.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On CalciMedica

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Atria Investments Inc lifted its position in CalciMedica by 136.5% during the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after buying an additional 15,296 shares during the period. Geode Capital Management LLC increased its stake in shares of CalciMedica by 51.2% in the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after acquiring an additional 22,525 shares in the last quarter. Finally, PVG Asset Management Corp purchased a new position in CalciMedica during the 3rd quarter valued at about $67,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.